[1]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.
|
[2]ZHOU M, HUANG Y, CHENG Z, et al.Revival, characterization, and hepatitis B virus infection of cryopreserved human fetal hepatocytes[J].J Virol Methods, 2014, 207:29-37.
|
[3]ZHOU M, ZHAO F, LI J, et al.Long-term maintenance of human fetal hepatocytes and prolonged susceptibility to HBV infection by co-culture with non-parenchymal cells[J].J Virol Methods, 2014, 195:185-193.
|
[4]VERRIER ER, COLPITTS CC, SCHUSTER C, et al.Cell culture models for the investigation of hepatitis B and D virus infection[J].Viruses, 2016, 8 (9) :261.
|
[5]HANTZ O, PARENT R, DURANTEL D, et al.Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells[J].J Gen Virol, 2009, 90 (Pt 1) :127-135.
|
[6]PHILLIPS S, CHOKSHI S, CHATTERJI U, et al.Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production[J].Gastroenterology, 2015, 148 (2) :403-414.
|
[7]YANG D, ZUO C, WANG X, et al.Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line[J].Proc Natl Acad Sci U S A, 2014, 111 (13) :e1264-e1273.
|
[8] YAN H, ZHONG G, XU G, et al.Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J].Elife, 2012, 1:e00049.
|
[9]KO C, LEE S, WINDISCH MP, et al.DDX3 DEAD-box RNA helicase is a host factor that restricts hepatitis B virus replication at the transcriptional level[J].J Virol, 2014, 88 (23) :13689-13698.
|
[10]NKONGOLO S, NI Y, LEMPP FA, et al.Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor[J].J Hepatol, 2014, 60 (4) :723-731.
|
[11]IWAMOTO M, WATASHI K, TSUKUDA S, et al.Evaluation and identification of hepatitis B virus entry inhibitors using Hep G2 cells overexpressing a membrane transporter NTCP[J].Biochem Biophys Res Commun, 2014, 443 (3) :808-813.
|
[12]NI Y, LEMPP FA, MEHRLE S, et al.Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes[J].Gastroenterology, 2014, 146 (4) :1070-1083.
|
[13]LI H, ZHUANG Q, WANG Y, et al.HBV life cycle is restricted in mouse hepatocytes expressing human NTCP[J].Cell Mol Immunol, 2014, 11 (2) :175-183.
|
[14]van de KLUNDERT MA, ZAAIJER HL, KOOTSTRA NA.Identification of FDA-approved drugs that target hepatitis B virus transcription[J].J Viral Hepat, 2016, 23 (3) :191-201.
|
[15] LUCIFORA J, XIA Y, REISINGER F, et al.Specific and nonhepatotoxic degradation of nuclear hepatitis B virus ccc DNA[J].Science, 2014, 343 (6176) :1221-1228.
|
[16]YAN R, ZHAO X, CAI D, et al.The interferon-inducible protein tetherin inhibits hepatitis B virus virion secretion[J].J Virol, 2015, 89 (18) :9200-9212.
|
[17]LI H, SHENG C, WANG S, et al.Removal of integrated hepatitis B virus DNA using CRISPR-Cas9[J].Front Cell Infect Microbiol, 2017, 7:91.
|
[18]LIU W, SONG H, CHEN Q, et al.Multidrug resistance protein 4is a critical protein associated with the antiviral efficacy of nucleos (t) ide analogues[J].Liver Int, 2016, 36 (9) :1284-1294.
|
[19]LIU N, JIAO T, HUANG Y, et al.Hepatitis B virus regulates apoptosis and tumorigenesis through the microRNA-15a-Smad7-transforming growth factor beta pathway[J].J Virol, 2015, 89 (5) :2739-2749.
|
[20]WIELAND SF.The chimpanzee model for hepatitis B virus infection[J].Cold Spring Harb Perspect Med, 2015, 5 (6) :a021469.
|
[21]LANFORD RE, GUERRA B, CHAVEZ D, et al.GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees[J].Gastroenterology, 2013, 144 (7) :1508-1517.
|
[22]ASABE S, WIELAND SF, CHATTOPADHYAY PK, et al.The size of the viral inoculum contributes to the outcome of hepatitis B virus infection[J].J Virol, 2009, 83 (19) :9652-9662.
|
[23]DUPINAY T, GHEIT T, ROQUES P, et al.Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island[J].Hepatology, 2013, 58 (5) :1610-1620.
|
[24]XIAO J, LIU R, CHEN C.Tree shrew (Tupaia belangeri) as a novel non-human primate laboratory disease animal model[J].Zool Res, 2017, 38 (3) :127-137.
|
[25]YAO YG.Creating animal models, why not use the Chinese tree shrew (Tupaia belangeri chinensis) ?[J].Zool Res, 2017, 38 (3) :118-126.
|
[26]TSUKIYAMA-KOHARA K, KOHARA M.Tupaia belangeri as an experimental animal model for viral infection[J].Exp Anim, 2014, 63 (4) :367-374.
|
[27]WANG Q, SCHWARZENBERGER P, YANG F, et al.Experimental chronic hepatitis B infection of neonatal tree shrews (Tupaia belangeri chinensis) :a model to study molecular causes for susceptibility and disease progression to chronic hepatitis in humans[J].Virol J, 2012, 9:170.
|
[28]FENG Y, FENG YM, FENG Y, et al.Identification and characterization of liver microRNAs of the Chinese tree shrew via deep sequencing[J].Hepat Mon, 2015, 15 (10) :e29053.
|
[29]FAN Y, YU D, YAO YG.Tree shrew database (Treeshrew DB) :a genomic knowledge base for the Chinese tree shrew[J].Sci Rep, 2014, 4:7145.
|
[30]WU X, XU H, ZHANG Z, et al.Transcriptome profiles using next-generation sequencing reveal liver changes in the early stage of diabetes in tree shrew (Tupaia belangeri chinensis) [J].J Diabetes Res, 2016, 2016:6238526.
|
[31]YU W, YANG C, BI Y, et al.Characterization of hepatitis E virus infection in tree shrew (Tupaia belangeri chinensis) [J].BMC Infect Dis, 2016, 16:80.
|
[32]YE L, HE M, HUANG Y, et al.Tree shrew as a new animal model for the study of lung cancer[J].Oncol Lett, 2016, 11 (3) :2091-2095.
|
[33]RUAN P, YANG C, SU J, et al.Histopathological changes in the liver of tree shrew (Tupaia belangeri chinensis) persistently infected with hepatitis B virus[J].Virol J, 2013, 10:333.
|
[34]ZHAO F, GUO X, WANG Y, et al.Drug target mining and analysis of the Chinese tree shrew for pharmacological testing[J].PLo S One, 2014, 9 (8) :e104191.
|
[35]BISSIG KD, WIELAND SF, TRAN P, et al.Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment[J].J Clin Invest, 2010, 120 (3) :924-930.
|
[36]ZHANG TY, YUAN Q, ZHAO JH, et al.Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen[J].Gut, 2016, 65 (4) :658-671.
|
[37]WASHBURN ML, BILITY MT, ZHANG L, et al.A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease[J].Gastroenterology, 2011, 140 (4) :1334-1344.
|
[38]BILITY MT, CHENG L, ZHANG Z, et al.Hepatitis B virus infection and immunopathogenesis in a humanized mouse model:induction of human-specific liver fibrosis and M2-like macrophages[J].PLo S Pathog, 2014, 10 (3) :e1004032.
|
[39]HAO YH, LI AY, DING HH, et al.Experimental study on duck hepatitis B virus infection model by different kinds of ducklings and antiviral effect[J].Chin J Comp Med, 2012, 22 (11) :23-26. (in Chinese) 郝友华, 李安意, 丁红晖, 等.不同种雏鸭建立鸭乙肝病毒感染模型及抗病毒效果的实验[J].中国比较医学杂志, 2012, 22 (11) :23-26.
|
[40]CAMPAGNA MR, LIU F, MAO R, et al.Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids[J].J Virol, 2013, 87 (12) :6931-6942.
|
[41]TOHIDI-ESFAHANI R, VICKERY K, COSSART Y.The early host innate immune response to duck hepatitis B virus infection[J].J Gen Virol, 2010, 91 (Pt 2) :509-520.
|
[42]REAICHE GY, LE MIRE MF, MASON WS, et al.The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis[J].Virology, 2010, 406 (2) :286-292.
|
[43]SAADE F, BURONFOSSE T, GUERRET S, et al.In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes[J].J Viral Hepat, 2013, 20 (4) :e56-e65.
|
[44]ROGGENDORF M, YANG D, LU M.The woodchuck:a model for therapeutic vaccination against hepadnaviral infection[J].Pathol Biol (Paris) , 2010, 58 (4) :308-314.
|
[45]MASON WS.Animal models and the molecular biology of hepadnavirus infection[J].Cold Spring Harb Perspect Med, 2015, 5 (4) :a021352.
|
[46]FLETCHER SP, CHIN DJ, CHENG DT, et al.Identification of an intrahepatic transcriptional signature associated with self-limiting infection in the woodchuck model of hepatitis B[J].Hepatology, 2013, 57 (1) :13-22.
|
[47]KOSINSKA AD, ZHANG E, JOHRDEN L, et al.Combination of DNA prime-adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model[J].PLo S Pathog, 2013, 9 (6) :e1003391.
|
[48]WANG BJ, TIAN YJ, MENG ZJ, et al.Establishing a new animal model for hepadnaviral infection:susceptibility of Chinese Marmota-species to woodchuck hepatitis virus infection[J].J Gen Virol, 2011, 92 (Pt 3) :681-691.
|
[49]LIU Y, WANG B, WANG L, et al.Transcriptome analysis and comparison of marmota monax and marmota himalayana[J].PLo S One, 2016, 11 (11) :e165875.
|
[50]FAN H, ZHU Z, WANG Y, et al.Molecular characterization of the type I IFN receptor in two woodchuck species and detection of its expression in liver samples from woodchucks infected with woodchuck hepatitis virus (WHV) [J].Cytokine, 2012, 60 (1) :179-185.
|
[51]YANG Y, ZHANG X, ZHANG C, et al.Molecular characterization of woodchuck CD4 (w CD4) and production of a depletion monoclonal antibody against w CD4[J].Mol Immunol, 2013, 56 (1-2) :64-71.
|
[52]YAN Q, LI M, LIU Q, et al.Molecular characterization of woodchuck IFI16 and AIM2 and their expression in woodchucks infected with woodchuck hepatitis virus (WHV) [J].Sci Rep, 2016, 6:28776.
|
[53]JIANG M, LIU J, ZHANG E, et al.Molecular characterization of woodchuck interleukin-10 receptor and enhanced function of specific T cells from chronically infected woodchucks following its blockade[J].Comp Immunol Microbiol Infect Dis, 2012, 35 (6) :563-573.
|
[54]WANG L, WANG J, LIU Y, et al.Molecular cloning, characterization and expression analysis of TGF-βand receptor genes in the woodchuck model[J].Gene, 2016, 595 (1) :1-8.
|
[55]ZHANG E, ZHANG X, LIU J, et al.The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection[J].PLo S One, 2011, 6 (10) :e26196.
|
[56]LU Y, WANG B, HUANG H, et al.The interferon-alpha gene family of Marmota himalayana, a Chinese marmot species with susceptibility to woodchuck hepatitis virus infection[J].Dev Comp Immunol, 2008, 32 (4) :445-457.
|
[57]WANG B, ZHU Z, ZHU B, et al.Nucleoside analogues alone or combined with vaccination prevent hepadnavirus viremia and induce protective immunity:alternative strategy for hepatitis B virus postexposure prophylaxis[J].Antiviral Res, 2014, 105:118-125.
|
[58]LIU J, ZHANG E, MA Z, et al.Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1blockade in chronic hepadnaviral infection[J].PLo S Pathog, 2014, 10 (1) :e1003856.
|
[59]PAN D, LIN Y, WU W, et al.Persistence of the recombinant genomes of woodchuck hepatitis virus in the mouse model[J].PLo S One, 2015, 10 (5) :e0125658.
|
[60]ZHANG E, KOSINSKA AD, MA Z, et al.Woodchuck hepatitis virus core antigen-based DNA and protein vaccines induce qualitatively different immune responses that affect T cell recall responses and antiviral effects[J].Virology, 2015, 475:56-65.
|
[61]MA Z, ZHANG E, YANG D, et al.Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses[J].Cell Mol Immunol, 2015, 12 (3) :273-282.
|
[62]MENG Z, ZHANG X, WU J, et al.RNAi induces innate immunity through multiple cellular signaling pathways[J].PLo S One, 2013, 8 (5) :e64708.
|
[63]QING Y, CHEN M, ZHAO J, et al.Construction of an HBV DNA vaccine by fusion of the GM-CSF gene to the HBV-S gene and examination of its immune effects in normal and HBV-transgenic mice[J].Vaccine, 2010, 28 (26) :4301-4307.
|
[64]DING C, WEI H, SUN R, et al.Hepatocytes proteomic alteration and seroproteome analysis of HBV-transgenic mice[J].Proteomics, 2009, 9 (1) :87-105.
|
[65]JIN Z, SUN R, WEI H, et al.Accelerated liver fibrosis in hepatitis B virus transgenic mice:involvement of natural killer T cells[J].Hepatology, 2011, 53 (1) :219-229.
|
[66]MENG Z, MA Z, ZHANG E, et al.Novel Woodchuck Hepatitis Virus (WHV) transgene mouse models show sex-dependent WHV replicative activity and development of spontaneous immune responses to WHV proteins[J].J Virol, 2014, 88 (3) :1573-1581.
|
[67]HUANG LR, GBEL YA, GRAF S, et al.Transfer of HBV genomes using low doses of adenovirus vectors leads to persistent infection in immune competent mice[J].Gastroenterology, 2012, 142 (7) :1447-1450.
|
[68]PENG XH, REN XN, CHEN LX, et al.High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/He N mice[J].World J Gastroenterol, 2015, 21 (12) :3527-3536.
|
[69]DIETZE KK, SCHIMMER S, KRETZMER F, et al.Characterization of the treg response in the hepatitis B virus hydrodynamic injection mouse model[J].PLo S One, 2016, 11 (3) :e0151717.
|
[70]WU J, HUANG S, ZHAO X, et al.Poly (I∶C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model[J].J Virol, 2014, 88 (18) :10421-10431.
|
[71]SONG J, ZHOU Y, LI S, et al.Susceptibility of different hepatitis B virus isolates to interferon-alpha in a mouse model based on hydrodynamic injection[J].PLo S One, 2014, 9 (3) :e90977.
|
[72]WANG J, WANG B, HUANG S, et al.Immunosuppressive drugs modulate the replication of hepatitis B virus (HBV) in a hydrodynamic injection mouse model[J].PLo S One, 2014, 9 (1) :e85832.
|
[73]LI L, SHEN H, LI A, et al.Inhibition of hepatitis B virus (HBV) gene expression and replication by HBx gene silencing in a hydrodynamic injection mouse model with a new clone of HBV genotype B[J].Virol J, 2013, 10:214.
|
[74] QI Z, LI G, HU H, et al.Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice[J].J Virol, 2014, 88 (14) :8045-8056.
|